Novel triglyceride and its use

By developing triglycerides or their optical isomers, the problem of HYA being solid and irritating at room temperature is solved, and its liquid state and good taste is achieved, ensuring the effect of exerting physiological functions in the body. It is suitable for a variety of applications field.

CN107922308BActive Publication Date: 2024-11-12NOSTER INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201680045378.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-06-02
Filing Date
2016-06-02
Publication Date
2024-11-12
Estimated Expiration
2036-06-02

AI Technical Summary

Technical Problem

10-hydroxy-cis-12-octadecanoic acid (HYA) has a high melting point and a irritating taste, resulting in it being solid at room temperature, poor uptake and operability, and lack of effective derivatives to exert its physiological function.

Method used

Develop triglycerides or their optical isomers, in which the fatty acid that forms an ester bond with glycerol is 10-hydroxy-cis-12-octadecanoic acid, ensuring that it is a liquid at room temperature and improving taste, thereby improving its uptake and Convenience of operation.

Benefits of technology

The liquid state and good taste of HYA are achieved, so that it can effectively exert physiological functions after hydrolysis by lipase in the body, such as improving lipid metabolism, enhancing intestinal immunity and inhibiting inflammation, suitable for edible oils, food, medicines and Cosmetics and other fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN107922308B_ABST
    Figure CN107922308B_ABST
Patent Text Reader

Abstract

The present invention provides novel HYA derivatives that have excellent physiological functions inherent to HYA and are easy to take and handle, and uses thereof. The present invention relates to a triglyceride or an optical isomer thereof in which at least one fatty acid that forms an ester bond with a hydroxyl group of glycerol is 10-hydroxy-cis-12-octadecenoic acid, and a composition (edible fats and oils, food, medicine, cosmetics, etc.) containing the same.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to novel triglycerides and compositions containing the same, as well as uses thereof, and specifically to triglycerides in which at least one fatty acid forming an ester bond with a hydroxyl group of glycerol is 10-hydroxy-cis-12-octadecenoic acid (hereinafter referred to as "HYA") or an optical isomer thereof.

[0002] In addition, the present invention also relates to the use of the triglyceride or its optical isomer as edible fat and oil, and a composition (food, medicine, cosmetic, feed, etc.) containing the triglyceride or its optical isomer. Background Art

[0003] In recent years, the physiological functions of rare fatty acids that exist only in a low proportion in the living body have attracted attention. For example, it is reported that conjugated fatty acids such as conjugated linoleic acid (non-patent document 1), ω3 polyunsaturated fatty acids such as eicosapentaenoic acid and docosahexaenoic acid (patent document 1) have lipid metabolism improvement effects, diabetes improvement effects, etc. For the intake of the above functional lipids with meals, it has received great attention, and products (foods, etc.) containing them have entered the market.

[0004] One of rare fatty acids includes hydroxylated fatty acids with hydroxyl groups in compounds. Up to now, there is no suitable supply source, and its physiological function has not been fully analyzed, and recently, it has been found that the linoleic acid etc. contained in a large number of vegetable oils are used as starting raw materials, and enzyme reaction is used to efficiently and selectively manufacture the method (patent documentation 2). And, while the supply method of various hydroxylated fatty acids can be ensured, the research on its physiological function is also actively carried out. In hydroxylated fatty acids, the inventor especially focuses on 10-hydroxy-adaptive-12-octadecenoic acid (HYA), and it is reported that HYA has an improvement effect on lipid metabolism abnormalities (patent documentation 3), an improvement effect on intestinal immunity (patent documentation 4), an inhibitory effect (non-patent documentation 2) of intestinal inflammation, etc.

[0005] Since it is easy to obtain high-purity HYA as described above, if HYA can be easily ingested, it is expected that its physiological functions will be utilized to promote the effective use of HYA. However, there are the following problems: HYA has a melting point of about 25°C (here, "about" means ±1°C) and is solid (or partially melted) at room temperature. Therefore, compared with liquid ingredients, its ease of ingestion and the operability when adding or mixing with other liquid or solid food ingredients are poor. In addition, the pungent taste of HYA itself also becomes an obstacle to ingestion.

[0006] On the other hand, no HYA derivatives capable of solving the above-mentioned problems have been reported so far.

[0007] Prior art literature

[0008] Patent Literature

[0009] Patent Document 1: Japanese Patent Application No. 2006-521368

[0010] Patent Document 2: International Publication No. 2013 / 168310

[0011] Patent Document 3: International Publication No. 2014 / 069227

[0012] Patent Document 4: International Publication No. 2014 / 129384

[0013] Non-patent literature

[0014] Non-patent document 1: Nagao, K., J. Biosci. Bioeng., 2005, vol. 100, no. 2, p. 152-157

[0015] Non-patent document 2: Miyamoto, J. et al., J. Biol. Chem., 2015, 290(5), 2902-2918 Summary of the invention

[0016] Problem that the invention aims to solve

[0017] An object of the present invention is to provide a novel HYA derivative which has the excellent physiological function of HYA and is easy to ingest and handle.

[0018] Solutions to the problem

[0019] The present inventors have conducted intensive studies in view of the above-mentioned problems and have found that a novel triglyceride in which at least one fatty acid forming an ester bond with the hydroxyl group of glycerol is 10-hydroxy-cis-12-octadecenoic acid or an optical isomer thereof is liquid at room temperature and has a good taste, thereby completing the present invention.

[0020] That is, the present invention is as follows:

[0021] [1] A triglyceride or an optical isomer thereof, wherein at least one fatty acid forming an ester bond with a hydroxyl group of glycerol is 10-hydroxy-cis-12-octadecenoic acid.

[0022] [2] The triglyceride or optical isomer thereof according to [1] above, wherein the two fatty acids forming an ester bond with the hydroxyl group of the glycerol are 10-hydroxy-cis-12-octadecenoic acid.

[0023] [3] The triglyceride or optical isomer thereof according to [1] above, wherein the three fatty acids forming ester bonds with the hydroxyl groups of the glycerol are 10-hydroxy-cis-12-octadecenoic acid.

[0024] [4] The triglyceride or optical isomer thereof according to [1] or [2] above, wherein the fatty acid forming an ester bond with the hydroxyl group of the glycerol other than 10-hydroxy-cis-12-octadecenoic acid is a fatty acid having 8 to 22 carbon atoms.

[0025] [5] The triglyceride or optical isomer thereof according to [4] above, wherein the fatty acid other than 10-hydroxy-cis-12-octadecenoic acid among the fatty acids forming an ester bond with the hydroxyl group of glycerol is a fatty acid derived from edible fats and oils.

[0026] [6] The triglyceride or optical isomer thereof according to [4] above, wherein, among the fatty acids forming an ester bond with the hydroxyl group of glycerol, the fatty acid other than 10-hydroxy-cis-12-octadecenoic acid is one or more selected from the group consisting of linoleic acid, α-linolenic acid, γ-linolenic acid, octadecatetraenoic acid, oleic acid, stearic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, arachidic acid, palmitoleic acid, eicosatrienoic acid (mead acid), and diho-γ-linolenic acid.

[0027] [7] The triglyceride or optical isomer thereof according to any one of [1] to [6] above, which is liquid at room temperature.

[0028] [8] An edible fat or oil comprising the triglyceride or an optical isomer thereof according to any one of [1] to [7] above.

[0029] [9] A food or food additive containing the triglyceride or an optical isomer thereof according to any one of [1] to [7] above.

[0030]

[10] A pharmaceutical composition comprising the triglyceride or an optical isomer thereof according to any one of [1] to [7] above.

[0031]

[11] A preventive or therapeutic agent for a disease, comprising a triglyceride or an optical isomer thereof according to any one of [1] to [7] above, wherein the disease is selected from obesity, diabetes, abnormal lipid metabolism, hyperlipidemia, fatty liver, ulcerative colitis, Crohn's disease, ulcer, irritable bowel syndrome, and inflammatory disease.

[0032]

[12] A cosmetic or cosmetic additive comprising the triglyceride or an optical isomer thereof according to any one of [1] to [7] above.

[0033]

[13] A feed or a feed supplement comprising the triglyceride or an optical isomer thereof according to any one of [1] to [7] above.

[0034] Effects of the Invention

[0035] According to the present invention, a novel triglyceride or an optical isomer thereof can be provided. The triglyceride or an optical isomer thereof of the present invention is a derivative of HYA, is liquid at room temperature, has a good taste, and is easy to take and handle.

[0036] In addition, after ingestion, the triglyceride or its optical isomer of the present invention will hydrolyze the ester bond of the triglyceride by lipase or the like in the body to release HYA, so it can be expected to exert excellent physiological functions (lipid metabolism abnormality improvement effect, intestinal immunity improvement effect, intestinal inflammation suppression effect, etc.) similar to the case of ingesting HYA itself alone.

[0037] Therefore, the triglyceride of the present invention or its optical isomer having the above-mentioned functions can be used as edible fats and oils, and can also be used as various foods and food additives. Furthermore, it can be used in various fields such as medicines, cosmetics, and feeds, and is therefore extremely useful industrially. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] [ Figure 1 ] is a graph showing the proportion of compound (I) in all triglycerides for each triglyceride mixture obtained by performing lipase exchange reaction for 1 hour and 4 hours in Example 4.

[0039] [ Figure 2 ] is a graph showing the results of TLC-based analysis of lipids extracted from each microorganism in Example 5.

[0040] [ Figure 3 ] shows a graph of the analysis curve based on gas chromatography for the fatty acid composition of lipids extracted from each microorganism in Example 5. DETAILED DESCRIPTION

[0041] Hereinafter, the present invention will be described in detail.

[0042] (definition)

[0043] In this specification, "fatty acid" refers to a monocarboxylic acid of a straight-chain or branched aliphatic hydrocarbon. The fatty acid may be a saturated fatty acid, or a monounsaturated fatty acid or a polyunsaturated fatty acid. In addition, a part of the aliphatic hydrocarbon chain may be substituted with a hydroxyl group or a carbonyl group. The range of the number of carbon atoms in the "fatty acid" is not particularly limited, but is preferably 6 to 26, more preferably 8 to 24, and most preferably 8 to 22.

[0044] In this specification, "saturated fatty acid" refers to a fatty acid having no unsaturated bond in its aliphatic hydrocarbon chain. In addition, in this specification, "monounsaturated fatty acid" refers to a fatty acid having one unsaturated bond in its aliphatic hydrocarbon chain. Further, in this specification, "polyunsaturated fatty acid" refers to a fatty acid having two or more unsaturated bonds in its aliphatic hydrocarbon chain.

[0045] In the present specification, "acyl" means an alkanoyl group or an alkenoyl group derived from a fatty acid.

[0046] (Compound of the present invention)

[0047] The compound of the present invention is a triglyceride in which at least one fatty acid forming an ester bond with the hydroxyl group of glycerol is 10-hydroxy-cis-12-octadecenoic acid or an optical isomer thereof, preferably a triglyceride in which one fatty acid forming an ester bond with the hydroxyl group of glycerol is 10-hydroxy-cis-12-octadecenoic acid or an optical isomer thereof, or a triglyceride in which two fatty acids forming an ester bond with the hydroxyl group of glycerol are 10-hydroxy-cis-12-octadecenoic acid or an optical isomer thereof.

[0048] Specifically, the compound of the present invention is a triglyceride represented by the following formula (I) or an optical isomer thereof (hereinafter, also referred to as compound (I)).

[0049] [Chemical formula 1]

[0050]

[0051] [Where R 1 , R 2 and R 3 are the same or different and represent acyl groups, and at least one of them is a 10-hydroxy-cis-12-octadecenoyl group represented by the following formula (II).

[0052] [Chemical formula 2]

[0053]

[0054] (In the formula, * represents the position of bonding to the oxygen atom in the compound represented by formula (I).)

[0055] In the compound (I) of the present invention, R 1 , R 2 or R 3 At least one of the acyl groups is a 10-hydroxy-cis-12-octadecenoyl group represented by formula (II). The 10-hydroxy-cis-12-octadecenoyl group may be bonded to any of the hydroxyl groups at the 1-position, 2-position and 3-position of glycerol in compound (I).

[0056] In the present invention, it can be R1 , R 2 or R 3 One or two of the acyl groups shown are 10-hydroxy-cis-12-octadecenoyl, or R 1 , R 2 or R 3 The acyl groups shown are all 10-hydroxy-cis-12-octadecenoyl, but preferably R 1 , R 2 or R 3 A compound wherein one or both of the acyl groups are 10-hydroxy-cis-12-octadecenoyl.

[0057] In the compound (I) of the present invention, R 1 , R 2 or R 3 The acyl group other than 10-hydroxy-cis-12-octadecenoyl group shown is not particularly limited in type, but is preferably an acyl group having 6 to 26 carbon atoms, more preferably an acyl group having 8 to 24 carbon atoms, and particularly preferably an acyl group having 8 to 22 carbon atoms.

[0058] Specific examples include: 9,12-octadecadienoic acid (linoleic acid) [18: 2, ω6], 6,9,12-octadecatrienoic acid (γ-linolenic acid) [18: 3, ω6], 8,11,14-eicosatrienoic acid (diho-γ-linolenic acid) [20: 3, ω6], 5,8,11,14-eicosatetraenoic acid (arachidonic acid) [20: 4, ω6], 7,10,13,16-docosatatetraenoic acid [22: 4, ω6], 4,7,10,13,16-docosapentaenoic acid [22: 5, ω6], 9,12,15-octadecatrienoic acid (α-linolenic acid) [18: 3, ω3], 6,9,12,15-octadecatrienoic acid (octadecatrienoic acid) [18: 4, ω3], 11,14,17-eicosatrienoic acid [20: 3, ω3], 8,11,14,17-eicosatetraenoic acid [20: 4, ω3], 5,8,11,14,17-eicosapentaenoic acid (eicosapentaenoic acid) [20: 5, ω3], 7,10,13,16,19-docosapentaenoic acid [22: 5, ω3], 4,7,10,13,16,19-docosahexaenoic acid (docosahexaenoic acid) [22: 6, ω3], 6,9-octadecadienoic acid [18: 2, ω9], 8,11-eicosadienoic acid [20: 2, ω9], 5,8,11-eicosatrienoic acid (mead acid) [20: 3, ω9], 9,11-conjugated linoleic acid [18: 2 ], 10,12-conjugated linoleic acid [18:2], 9,11,13-conjugated linolenic acid [18:3], 8,10,12-conjugated linolenic acid [18:3], 9,11,15-conjugated linolenic acid [18:3], 10,12,15-conjugated linolenic acid [18:3], 6,9,11-conjugated linolenic acid [18:3], 6,10,12-conjugated linolenic acid [18:3]; acyl groups derived from monounsaturated fatty acids such as oleic acid (18:1, ω9), palmitoleic acid (16:1, ω7), elaidic acid (18:1, ω9), eicosenoic acid (20:1, ω9), erucic acid (22:1, ω9), neuraminic acid (24:1, ω9); acyl groups derived from hexanoic acid ( Preferably, the acyl groups are saturated fatty acids such as linoleic acid (6:0), caprylic acid (8:0), capric acid (10:0), lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), margaric acid (17:0), stearic acid (18:0), arachidic acid (20:0), behenic acid (22:0), tetracosanoic acid (24:0), and hexacosanoic acid (26:0). Among them, acyl groups derived from fatty acids having 8 to 22 carbon atoms such as linoleic acid, α-linolenic acid, γ-linolenic acid, oleic acid, stearic acid, arachidic acid, eicosapentaenoic acid, docosahexaenoic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, arachidic acid, palmitoleic acid, elaidic acid, diho-γ-linolenic acid, octadecatetraenoic acid, and eicosatrienoic acid are particularly preferred.

[0059] In addition, as the acyl group other than 10-hydroxy-cis-12-octadecenoyl group in the compound (I) of the present invention, preferred acyl groups include acyl groups derived from fatty acids derived from edible fats and oils such as vegetable fats and oils or animal fats and oils.

[0060] In the present specification, "fatty acids derived from edible oils and fats such as vegetable oils and fats or animal oils" refer to fatty acids derived from oils and fats obtained by extracting and refining fats contained in plants, fish and other animals. Specifically, for example, linoleic acid, α-linolenic acid, γ-linolenic acid, stearic acid, oleic acid, stearic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, arachidic acid, palmitoleic acid, eicosatrienoic acid, diho-γ-linolenic acid, etc.

[0061] When the compound (I) of the present invention has two acyl groups other than 10-hydroxy-cis-12-octadecenoyl group, they may be the same or different, and they may be bonded to any hydroxyl group at position 1, 2 or 3 of glycerol.

[0062] The compound (I) of the present invention may also be R 1 , R 2 or R 3 A triglyceride in which one of the acyl groups is 10-hydroxy-cis-12-octadecenoyl, R 1 , R 2 or R 3 The acyl groups shown are two 10-hydroxy-cis-12-octadecenoyl triglycerides, and R 1 , R 2 or R 3 All the acyl groups shown are mixtures of two or more of 10-hydroxy-cis-12-octadecenoyl triglycerides.

[0063] Alternatively, you can also 1 , R 2 or R 3 A mixture of two or more triglycerides in which one or two of the acyl groups shown is 10-hydroxy-cis-12-octadecenoyl.

[0064] When the compound (I) of the present invention has isomers such as optical isomers, stereoisomers, positional isomers, etc., any isomers and mixtures thereof are also included in the compound (I) of the present invention.

[0065] When the compound (I) of the present invention has optical isomers, the optical isomers can be obtained as optically pure compounds by known synthesis methods, separation methods (crystallization, separation by high performance liquid chromatography using an optically active column, enzymatic methods, etc.). These optical isomers can be used in a mixed state, or optically pure compounds obtained by separation can be used alone, or they can be used in combination.

[0066] The melting point of the compound (I) of the present invention is below the melting point of HYA (about 25°C). The compound (I) of the present invention is preferably a liquid at standard temperature, and more preferably a liquid at room temperature. The standard temperature and room temperature here refer to the standard temperature (20°C) and room temperature (15°C to 25°C) specified in the 16th revised edition of the Japanese Pharmacopoeia General Rules and the 17th revised edition of the Japanese Pharmacopoeia General Rules. In addition, "about" here means ±1°C.

[0067] (Method for producing compound (I) of the present invention)

[0068] There is no particular limitation on the method for preparing the compound (I) of the present invention, and examples thereof include: a method for preparing a triglyceride by transesterifying with HYA or its ester or activated form (e.g., acyl halide, active ester, acid anhydride, etc.), or a method for preparing a triglyceride by transesterifying with HYA and fatty acids other than it or their ester or activated form (e.g., acyl halide, active ester, acid anhydride, etc.) simultaneously or sequentially (Preparation 1); and a method for preparing a glycerol by preparing a hydroxyl group of glycerol by preparing a ... When selecting the preparation method and reaction conditions, the preferred ones can be selected considering the stability of the raw material compound and the product, and a plurality of preparation methods can be combined. It is also possible to further appropriately combine reaction steps such as protection and deprotection. Furthermore, it is also possible to manufacture by a preparation method (Preparation Method 3) based on the accumulation of fats and oils using microorganisms.

[0069] HYA used in each of the above-mentioned preparation methods can be prepared by the method described in Patent Document 2 or the like. The trilinolein and glycerol used in each of the above-mentioned preparation methods can be directly used as commercial products of Tokyo Chemical Industry Co., Ltd. or the like. In addition, triglycerides other than trilinolein can be used as commercial products, or can be prepared and used by an esterification reaction between a hydroxyl group of glycerol and a fatty acid or an activated form thereof (e.g., an acyl halide, an active ester, an acid anhydride, etc.). The above-mentioned esterification reaction can be carried out by the same method as Preparation Method 2.

[0070] Next, the preparation method 1 of the compound (I) of the present invention is described.

[0071] As the transesterification reaction in Production Method 1, any of an enzyme reaction and a chemical reaction may be used, but an enzyme reaction is preferred because it can be carried out with high selectivity under simple and mild conditions.

[0072] The enzyme used in the transesterification reaction of the preparation method 1 is not particularly limited as long as it is an enzyme that can convert at least one acyl group of triglyceride into 10-hydroxy-cis-12-octadecenoyl group, and examples thereof include lipase, esterase, etc., among which lipase is preferred. Lipase can be obtained as a commercial product from Novozymes, Amano Enzyme Co., Ltd., Meito Sangyo Co., Ltd., Sigma-Aldrich Co., Ltd., etc.

[0073] In the enzyme reaction of Preparation Method 1, it is desirable that the water content in the reaction substrate and solvent is as low as possible so that the triglyceride as the reaction substrate and reaction product is not hydrolyzed. The reaction can be carried out without a solvent or in various non-aqueous solvents (e.g., non-polar solvents such as n-heptane, n-hexane, isooctane, etc.), and the reaction without a solvent is more preferred. Furthermore, in order to limit the mixing of water into the substrate and solvent used, it is preferred to replace the gas part of the reaction system with an inert gas such as nitrogen or argon.

[0074] The reaction temperature in Preparation Method 1 varies depending on the presence or absence of a solvent, the type of solvent when a solvent is used, the type of enzyme, the type of triglyceride or fatty acid as a reaction substrate, etc., but is generally 4°C to 100°C, preferably 20°C to 70°C, and more preferably 30°C to 50°C.

[0075] The reaction time in Preparation Method 1 varies depending on the presence or absence of a solvent, the type of solvent when a solvent is used, the type of enzyme, the type of triglyceride or fatty acid as a reaction substrate, etc., but is generally 1 to 168 hours, preferably 5 to 48 hours.

[0076] As the triglyceride used as the reaction substrate in the preparation method 1, as long as the compound (I) of the present invention can be obtained by the transesterification reaction with HYA, it can be used without particular limitation. For example, triglycerides such as trilinoleic acid glycerol having three 9,12-octadecadienoyl groups and trioleic acid glycerol having three 9-octadecenoyl groups are commercially available and easy to obtain, and thus can be suitably used as raw materials. In addition, edible fats and oils are also commercially available and easy to obtain, and thus can be suitably used as raw materials.

[0077] The amount of HYA used in the preparation method 1, or the sum of the amounts of HYA and other fatty acids used, is preferably 10% to 500% by weight, particularly preferably 20% to 100% by weight, relative to triglycerides. In addition, when HYA and other esters or activated forms of fatty acids are used as raw materials, the amounts can be converted to the amount of HYA or the amount of other fatty acids and used.

[0078] The amount of the enzyme used in Production Method 1 is preferably 1 to 100% by weight, more preferably 1 to 50% by weight, and particularly preferably 1 to 20% by weight, relative to triglyceride.

[0079] Next, the preparation method 2 of the compound (I) of the present invention is described.

[0080] The esterification step in the production method 2 can be carried out by using an enzyme reaction or a chemical reaction, but it is preferable to use an enzyme reaction because the reaction operation is simple and the reaction conditions are mild.

[0081] The enzyme used for esterification of glycerol in Production Method 2 is not particularly limited as long as it can convert into Compound (I) of the present invention, and examples thereof include lipase and esterase, among which lipase is preferred.

[0082] In the esterification step of Preparation Method 2, it is desirable that the water content in the reaction substrate and the solvent is as low as possible so that the triglyceride as the reaction product is not hydrolyzed. The reaction can be carried out without a solvent or in various non-aqueous solvents (e.g., non-polar solvents such as n-heptane, n-hexane, isooctane, etc.), but the reaction without a solvent is more preferred. Furthermore, in order to remove water from the reaction system to shift the equilibrium of the reaction, promote the esterification reaction, or reduce the water content in the reaction substrate and the solvent used, the reaction can also be carried out under reduced pressure.

[0083] The reaction temperature in Preparation Method 2 varies depending on the presence or absence of a solvent, the type of solvent when a solvent is used, the type of enzyme, the type of fatty acid or its activated form as a reaction substrate, etc., but is generally 4°C to 100°C, preferably 20°C to 70°C, and more preferably 30°C to 50°C.

[0084] The reaction time in Preparation Method 2 varies depending on the presence or absence of a solvent, the type of solvent when a solvent is used, the type of enzyme, the type of fatty acid or its activated form as a reaction substrate, etc., but is generally 1 hour to 168 hours, preferably 5 hours to 120 hours.

[0085] The amount of HYA used as the reaction substrate in Preparation 2, or the sum of the amounts of HYA and other fatty acids used, is preferably 1000 to 10000% by weight, more preferably 1500 to 8000% by weight, and particularly preferably 2000 to 5000% by weight, relative to glycerol. In addition, when each activated form of HYA and other fatty acids is used as a raw material, the above amounts can be converted into the amount of HYA or the amount of other fatty acids and used.

[0086] The amount of the enzyme used is preferably 1 to 100% by weight, more preferably 10 to 90% by weight, and particularly preferably 30 to 80% by weight, relative to glycerol used as a reaction substrate in Preparation Method 2.

[0087] The enzyme used in the enzyme reaction adopted in the above-mentioned preparation methods 1 and 2 can be an enzyme immobilized by utilizing various carriers, or a free enzyme, but from the aspect that the activity is high and can be recovered and repeatedly used even in an anhydrous reaction system or a reaction system with less water, an immobilized enzyme is more preferred. The above-mentioned enzyme can be either an enzyme after purification or a crude purified product. Alternatively, the enzyme can be expressed by a bacterium such as Escherichia coli and the bacterium itself can be used, or the culture fluid of the bacterium can be used.

[0088] In the production method based on oil synthesis using microorganisms (Production Method 3), as the microorganisms used in the production, there can be listed fungi such as zygomycetes belonging to the genus Basidiobolus (Basidiobolus magnus, Basidiobolusranarum, Basidiobolus haptosporus, etc.), Pleurotus ostreatus, etc., but as long as they are microorganisms with the ability to synthesize triglycerides, their types are not limited.

[0089] (Edible fats and oils of the present invention)

[0090] The present invention provides edible fats and oils containing the compound (I) of the present invention (hereinafter also referred to as "edible fats and oils of the present invention").

[0091] That is, the compound (I) of the present invention can be used as edible fats and oils alone or in combination with other edible fats and oils. The content of the compound (I) of the present invention in the edible fats and oils of the present invention is not particularly limited, and is usually equivalent to more than 5% by weight of the total amount of edible fats and oils, preferably more than 20% by weight, and more preferably more than 50% by weight. From the aspect of obtaining excellent taste and physiological functions, it is particularly preferred to use it alone as edible fats and oils.

[0092] In the edible oil of the present invention, conventional ingredients (food additives, etc.) for edible oils and fats may be contained within the scope that does not destroy the characteristics of the present invention. As these ingredients, for example, emulsifiers, antioxidants / anti-deterioration agents, defoamers, crystal modifiers, etc. may be cited.

[0093] Examples of the emulsifier include fatty acid glycerides, polyglycerol fatty acid esters, sucrose fatty acid esters, polyglycerol condensed ricinoleic acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, and organic acid monoglycerides.

[0094] Examples of the antioxidant / anti-degradation agent include tocopherols, flavonoid derivatives, gallic acid derivatives, catechins and their esters, lignans (such as sesamin), fucic acid, sesamol, and terpenes.

[0095] Examples of the defoaming agent include silicone oil and the like.

[0096] Examples of the crystal modifier include triacylglycerol, diacylglycerol, monoglyceride, heptaglyceride, decaglyceride, waxes, and sterol esters other than the compound (I) of the present invention.

[0097] In addition, spices, colorants, etc. may be added. Examples of spices include capsaicin, anethole, eugenol, eucalyptol, zingerone, etc. Examples of colorants include carotene, astaxanthin, etc.

[0098] Furthermore, the edible oils and fats of the present invention may also contain various nutrients (sugars, proteins, etc.), various vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K, etc.), various minerals (magnesium, zinc, iron, sodium, potassium, selenium, etc.), etc. as needed.

[0099] (Food or food additive of the present invention)

[0100] The present invention provides a food or food additive containing the compound (I) of the present invention (hereinafter also referred to as "the food or food additive of the present invention" in this specification).

[0101] The food or food additive of the present invention is not particularly limited as long as it is in an orally ingestible form such as a solution, a suspension, an emulsion, a gel, a powder, or a solid molded product.

[0102] Specific examples of the food or food additive of the present invention include: supplements (powders, granules, soft capsules, hard capsules, tablets, chewable tablets, rapidly disintegrating tablets, syrups, liquids, etc.), beverages (carbonated beverages, lactic acid beverages, sports drinks, fruit juice drinks, vegetable beverages, soy milk beverages, coffee beverages, tea beverages, powdered beverages, concentrated beverages, nutritional beverages, alcoholic beverages, etc.), snacks (soft gelatin, jelly, chewing gum, chocolate, cookies, candy, caramel, Japanese snacks, snacks, etc.), fast food (instant noodles, soft canned foods, canned foods, microwave foods, instant soups / miso soups, freeze-dried foods, etc.), oily foods (mayonnaise, salad dressing, butter, cream, margarine, etc.), flour products (bread, pasta, noodles, cake flour, bread crumbs, etc.), seasonings (sauces, tomato processed seasonings, flavor seasonings, cooking combinations, soups, etc.), livestock processed products (meat ham / sausages, etc.), etc.

[0103] The content of the compound (I) of the present invention in the food or food additive of the present invention is 5 to 90 wt %, preferably 10 to 80 wt %, more preferably 20 to 70 wt %, relative to the total amount of the food or food additive.

[0104] The daily intake of the food or food additive of the present invention can be appropriately set according to the age of the subject to be ingested, the condition and severity of the disease to be improved by ingestion, the dosage form of the food, etc., and the intake of the compound (I) of the present invention is preferably set to the daily intake calculated as HYA as described later.

[0105] The food or food additive of the present invention can be formulated with various nutrients (sugars, proteins, etc.), various vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K, etc.), various minerals (magnesium, zinc, iron, sodium, potassium, selenium, etc.), dietary fiber, foods reported to have physiological functions (royal jelly, propolis, chitin, etc.), etc. as needed.

[0106] In addition, conventional food additives may be added to the food or food composition of the present invention as needed, such as emulsifiers (glycerol fatty acid esters, sucrose fatty acid esters, etc.), thickeners and stabilizers (pectin, sodium carboxymethyl cellulose, etc.), antioxidants (mixed vitamin E, sodium isoascorbate, etc.), preservatives (sodium benzoate, sorbic acid, etc.), glossing agents (shellac, beeswax, etc.), sweeteners (xylitol, aspartame, etc.), acidulants (citric acid, malic acid, etc.), bittering agents (naringin, etc.), seasonings (sodium L-glutamate, disodium 5'-inosinic acid, etc.), coloring agents (gardenia yellow, red No. 2, etc.), flavors (sweet orange flavor, vanillin, etc.), manufacturing agents (salt water, binders, etc.), etc.

[0107] The food or food additive of the present invention can be prepared by adding the above-mentioned various nutrients, various vitamins and the like, and conventional food additives to the compound (I) of the present invention as required, and then preparing the food or food additive by a conventional production method.

[0108] It should be noted that the edible oils and fats, foods or food additives of the present invention also include those classified as health foods, functional foods, health functional foods (for example, specific health foods, functional foods, etc.), special purpose foods (for example, foods for patients, etc.), edible oils and fats and foods marked with disease risk reduction labels, etc.

[0109] Here, as a "disease risk reduction mark", for example, there can be cited: a mark indicating that it is a substance for treating, improving, inhibiting and / or preventing a disease that can be improved by HYA. Therefore, the edible oil, food or food additive of the present invention can be provided as an edible oil, food or food additive with a mark indicating that it is used for improving and / or preventing a disease that can be improved by HYA, such as obesity, diabetes, lipid metabolism disorders, hyperlipidemia, fatty liver, inflammatory bowel disease (ulcerative colitis, Crohn's disease, pseudomembranous colitis, etc.), ulcer, irritable bowel syndrome, and other various inflammatory diseases (for example: gout, arthritis, polyneuritis, polyradiculitis, hepatitis, bronchitis, pneumonia, nephritis, cystitis, periodontitis, dermatitis, atopic dermatitis, etc.).

[0110] (Pharmaceutical composition of the present invention)

[0111] The present invention provides a pharmaceutical composition containing the compound (I) of the present invention (hereinafter also referred to as "the pharmaceutical composition of the present invention" in this specification).

[0112] The pharmaceutical composition of the present invention can be used in animals as a preventive agent for preventing the following diseases, or as a therapeutic agent for treating, improving, or inhibiting the following diseases, wherein the diseases are diseases that can be improved by using HYA, such as obesity, diabetes, abnormal lipid metabolism, hyperlipidemia, fatty liver, inflammatory bowel disease (ulcerative colitis, Crohn's disease, pseudomembranous colitis, etc.), ulcer, irritable bowel syndrome, and other various inflammatory diseases (such as gout, arthritis, polyneuritis, polyradiculitis, hepatitis, bronchitis, pneumonia, nephritis, cystitis, periodontitis, dermatitis, atopic dermatitis, etc.).

[0113] Here, “animals” include humans, and mammals such as dogs, cats, rabbits, hamsters, rats, mice, cows, pigs, sheep, horses, donkeys, and camels.

[0114] The pharmaceutical composition of the present invention is not particularly limited, and can be provided in the following forms, for example: oral preparations in various dosage forms such as powders, granules, pills, soft capsules, hard capsules, tablets, chewable tablets, rapidly disintegrating tablets, syrups, liquids, suspensions, and emulsions; and non-oral preparations such as suppositories, ointments, creams, gels, patches, inhalants, and injections.

[0115] The pharmaceutical composition of the present invention can be prepared by adding various additives to the compound (I) of the present invention as needed, and following conventional pharmaceutical preparation methods, such as the methods described in the sixteenth revised edition of the Japanese Pharmacopoeia General Rules [2], the seventeenth revised edition of the Japanese Pharmacopoeia General Rules [3], etc.

[0116] In the present invention, there are no particular restrictions on additives that can be used for formulation purposes, and examples thereof include: animal and plant oils such as soybean oil, safflower oil, olive oil, germ oil, sunflower oil, butter, and sardine oil; polyols such as polyethylene glycol, propylene glycol, glycerol, and sorbitol; surfactants such as sorbitan fatty acid esters, sucrose fatty acid esters, fatty acid glycerides, and polyglycerol fatty acid esters; solvents such as purified water, sterile purified water, water for injection, physiological saline, ethanol, and isopropanol; lactose, starch, crystalline cellulose, D-mannose, and the like. Excipients such as alcohol, soy lecithin, gum arabic, sorbitol liquid, maltose; binders such as pretreated starch, carboxymethyl cellulose, hydroxypropyl cellulose, shellac; disintegrants such as cross-linked polyvinylpyrrolidone, povidone, dextrin; lubricants such as magnesium silicate, aluminum stearate, talc; sweeteners such as aspartame, licorice extract, saccharin sodium; colorants such as yellow iron oxide, brown iron oxide, black iron oxide, food blue No. 1, food red No. 2; pH adjusters such as hydrochloric acid, citric acid, sodium citrate, potassium hydroxide, sodium hydroxide; flavors such as bitter essence, etc.

[0117] It should be noted that, when a liquid preparation is prepared, a solid preparation which is dissolved or suspended in water or other appropriate solvents and used at the time of use can also be prepared. In addition, tablets and granules can also be coated using a well-known method.

[0118] In the pharmaceutical composition of the present invention, the compound (I) of the present invention may be used in combination with a therapeutic drug for the above-mentioned diseases that the pharmaceutical composition of the present invention can improve or prevent, within the range not impairing the effects of the present invention.

[0119] Examples of drugs that can be used in combination with the pharmaceutical composition of the present invention (hereinafter referred to as "combination drugs") include sulfonylurea drugs (tolbutamide, glyburide, glipidazole, glimepiride, etc.), biguanide drugs (metformin hydrochloride, etc.), α-glucosidase inhibitors (voglibose, acarbose, etc.), thiazolidine derivatives (pioglitazone hydrochloride, etc.) and other diabetes therapeutic drugs; statins (pravastatin sodium, simvastatin, pitavastatin calcium, etc.), anion exchange resins (cholestyramine, colestilan, etc.), fibrates (clofibrate, clinofibrate, etc.), nicotinic acid drugs (vitamin E nicotinate, nicotinamide, etc.); salicylic acid preparations (mesalazine, etc.), continuous Sulfonamides (sulfasalazine, etc.), adrenocortical steroids (betamethasone, prednisolone, etc.), molecular targeted therapy drugs (infliximab, adalimumab, etc.), immunosuppressants (azathioprine, etc.), etc., for the treatment of inflammatory bowel diseases (Crohn's disease, ulcerative colitis, pseudomembranous colitis, etc.); anticholinergic drugs (pentasyl hydrochloride, benzylmethoxazole, etc.), gastrointestinal motility regulators (trimebutine, etc.), synthetic polymer compounds (calcium polycarbophil, etc.), lactic acid bacteria preparations, etc., for the treatment of irritable bowel syndrome; gout attack preventive drugs (colchicine, etc.), uric acid excretion promoters (probenecid, bucolome, benzbromarone, etc.), uric acid production inhibitors (allopurinol, etc.), etc.; non-steroidal anti-inflammatory drugs (non-steroidal anti-inflammatory drugs, non ... Arthritis and neuritis treatment drugs such as anti-inflammatory drugs (mefenamic acid, ketoprofen, diclofenac sodium, etc.), bioactive drugs (cyclosporine, etc.); hepatitis treatment drugs such as interferon preparations (interferon β, interferon α-2a, etc.), anti-hepatitis virus drugs (ribavirin, lamivudine, etc.), liver function improvement drugs (glycyrrhizin preparations, glucuronic acid, tiopronin, etc.); bronchitis treatment drugs such as β-stimulants (ephedrine hydrochloride, dl-methylephedrine hydrochloride, trotoquinol hydrochloride, etc.), theophylline drugs (dihydroxypropylphylline, aminophylline, etc.), anticholinergic drugs (tiotropium bromide hydrate, etc.); pneumonia treatment drugs such as macrolide antibiotics (clarithromycin, azithromycin, etc.), new quinolone antibiotics (levofloxacin, garenoxacin, etc.); blood Nephritis treatment drugs such as angiotensin converting enzyme inhibitors (enalapril maleate, delapril hydrochloride, etc.), angiotensin II receptor antagonists (losartan potassium, candesartan cilexetil, etc.); cystitis treatment drugs such as new quinolone antibiotics (ofloxacin, levofloxacin, norfloxacin, etc.), penicillin antibiotics (amoxicillin, ampicillin, cloxacillin, etc.), cephalosporin antibiotics (cephalexin hydrochloride, ceftriaxone hydrochloride, etc.), traditional Chinese medicine (Bawei Dihuang Pills, Zhuling Decoction, etc.); periodontal disease treatment drugs such as cephalosporin antibiotics (cephalexin, etc.), bactericides (benzethonium chloride, chlorhexidine hydrochloride, etc.); dermatitis and atopic dermatitis treatment drugs such as non-steroidal anti-inflammatory drugs (bufenamic acid, flufenamic acid butyl, etc.), antipruritic drugs (crotamiton, etc.);Immunomodulators (tacrolimus hydrate, etc.) and other atopic dermatitis treatment drugs;

[0120] When the pharmaceutical composition of the present invention is made into a non-oral preparation such as an injection, the composition is not particularly limited, and is preferably administered intravenously, intraperitoneally, intramuscularly, subcutaneously, percutaneously, intraarticularly, intrasynovially, intraperiosteally, sublingually, orally, and is particularly preferably administered intravenously or intraperitoneally. Intravenous administration can be any of drip injection and push injection.

[0121] The content of the compound (I) of the present invention in the pharmaceutical composition of the present invention is 5 to 100 wt %, preferably 10 to 90 wt %, more preferably 20 to 80 wt % relative to the total amount of the pharmaceutical composition of the present invention.

[0122] The dosage of the pharmaceutical composition of the present invention can be appropriately determined according to the type, age and weight of the animal to be administered, the condition and severity, the dosage form of the pharmaceutical composition, the method of administration, the type of combined drug, etc. For example: when the pharmaceutical composition of the present invention is orally administered to humans, it can be administered in the range of 0.02 mg / kg to 100 mg / kg body weight per day for adults, preferably in the range of 0.2 mg / kg to 50 mg / kg body weight, based on the total amount of HYA converted as an active ingredient. In addition, when it is administered to humans non-orally, it can be administered in the range of 0.002 mg / kg to 50 mg / kg body weight, preferably in the range of 0.02 mg / kg to 50 mg / kg body weight. The above amount can be administered once a day or divided into multiple times (2 to 5 times) regardless of oral or non-oral administration.

[0123] The administration period of the pharmaceutical composition of the present invention can be appropriately determined according to the state, condition, severity of the animal to be administered, and is generally 1 to 90 days, preferably 7 to 30 days.

[0124] (Cosmetics or cosmetic additives of the present invention)

[0125] The present invention provides a cosmetic or a cosmetic additive containing the compound (I) of the present invention (hereinafter, also referred to as "the cosmetic or cosmetic additive of the present invention" in this specification).

[0126] The cosmetic of the present invention can be produced by adding various additives to the compound (I) of the present invention as required, based on the above-mentioned method for producing the pharmaceutical composition.

[0127] The cosmetics of the present invention can be made into skin cosmetics such as creams, gels, emulsions, beauty essences, lotions, microemulsion essences, and facial masks; color cosmetics such as foundations, lipsticks, eye shadows, and blushers; cleansing cosmetics such as cleansing oils and cleansing creams; hair cosmetics such as shampoos and conditioners; and various forms of cosmetics such as bath preparations.

[0128] To the cosmetics of the present invention, active ingredients such as anti-wrinkle / anti-aging agents, anti-inflammatory agents, skin roughness preventive agents, cell activation / wound healing agents, whitening agents, oils (animal and plant oils and fats, waxes, esters, higher fatty acids, higher aliphatic alcohols, etc.), surfactants, solvents, thickeners, moisturizers, antioxidants, preservatives, pH adjusters, pigments, fragrances, etc., which are additives commonly used in cosmetics, can be added within the range that does not impair the characteristics of the present invention.

[0129] The cosmetic additive of the present invention can be prepared into an oily, suspension, emulsion, paste, powder, granular or other form by adding the above-mentioned oil, surfactant, solvent, thickener, pigment or the like to the compound (I) of the present invention as required, based on the above-mentioned method for producing the pharmaceutical composition.

[0130] The content of the compound (I) of the present invention in the cosmetic or cosmetic additive of the present invention is 5 to 70 wt %, preferably 10 to 60 wt %, more preferably 20 to 50 wt % relative to the total amount of the cosmetic etc. of the present invention.

[0131] (Feed or feed additive of the present invention)

[0132] The present invention provides a feed or a feed additive containing the compound (I) of the present invention (hereinafter also referred to as "the feed or feed additive of the present invention" in this specification).

[0133] The feed or feed additive of the present invention can be prepared in the form of oil, suspension, emulsion, gel, powder, granule, tablet and the like.

[0134] Examples of the feed or feed additive of the present invention include pet food, livestock or aquaculture feed additives, and the like.

[0135] The feed or feed additive of the present invention can be prepared by mixing the compound (I) of the present invention with feed excipients, diluents, etc. according to a common method.

[0136] As for the excipients and diluents for feed, any excipients and diluents can be used without particular limitation as long as they do not destroy the characteristics of the present invention, and examples thereof include: polysaccharides such as gum arabic, carrageenan, agar, xanthan gum, chitosan, cellulose, and locust bean gum; monosaccharides or disaccharides such as glucose, lactose, maltose, and sucrose; sugar alcohols such as glycerol, sorbitol, and D-mannitol; proteins such as albumin, casein, gluten, and gelatin; grain flours such as soybean meal, flour, soybean meal, and corn meal; yeasts such as brewer's yeast, baker's yeast, and brewer's yeast; fats and oils such as hydrogenated oil, vegetable oils and animal oils; clay minerals such as kaolin, zeolite, talc, vermiculite, and bentonite; silicic acid or salts thereof such as diatomaceous earth, hydrous silicon dioxide, silicic acid, light silicon dioxide, silicon dioxide, calcium silicate, and magnesium silicate; hydrocarbons such as light liquid paraffin and liquid paraffin; waxes such as carnauba wax, and the like.

[0137] In addition, as long as the characteristics of the present invention are not destroyed, amino acids such as glycine, DL-alanine, and sodium L-glutamate; vitamins such as L-ascorbic acid, ergocalciferol, thiamine hydrochloride, cholecalciferol, vitamin A powder, vitamin D powder, and riboflavin; minerals such as potassium chloride, ferric citrate, and calcium gluconate; and additives for supplementing nutrients such as pigments such as astaxanthin and canthaxanthin may be further added to the feed or feed additive of the present invention.

[0138] The content of the compound (I) of the present invention in the feed or feed additive of the present invention is 1 to 70 wt %, preferably 3 to 50 wt %, more preferably 5 to 30 wt % relative to the total amount of the feed of the present invention.

[0139] Example

[0140] The present invention will be described in more detail below with reference to Examples and Experimental Examples, but the present invention is not limited thereto and may be modified without departing from the scope of the present invention.

[0141] In the following examples, proton NMR ( 1 H NMR) spectra were measured using AVANCE III500 manufactured by Bruker Corporation, using deuterated chloroform as the solvent. 1 H NMR data are reported as chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet, dt = doublet of triplet, tt = triplet of triplet, brs = broad singlet, sep = septuple), coupling constant (Hz), integration, and assignment.

[0142] High-resolution mass spectrometry was performed using a high-performance liquid chromatography-mass spectrometer (LCMS) (LCMS-2020) manufactured by Shimadzu Corporation.

[0143] The melting point (mp) was measured using a melting point meter (MP-J3) manufactured by Anatec Yanaco Co., Ltd.

[0144] In the following examples, the compound (I) of the present invention was prepared based on the above-mentioned preparation method 1. In the preparation of the compound (I) of the present invention, commercially available trilinoleylglycerol (manufactured by Tokyo Chemical Industry Co., Ltd.) was used as a reaction substrate, and HYA was prepared and used by the method described in Patent Document 2. Other raw material compounds and reagents may be commercially available products as they are, or may be prepared by a method known per se or a method based thereon.

[0145] [Example 1] Di(cis,cis-9,12-octadecadienoyl)(10-hydroxy-cis-12-octadecenoyl)propylene glycol

[0146] Trilinoleyl (10 g), transesterification enzyme (lipase) (Novozymes, Lipozyme RMIM, 1 g), and HYA (5 g) were added to a 100 mL reaction container (medium bottle), and the gas phase of the reaction system was replaced with nitrogen, followed by stirring at 40° C. for 72 hours. A 0.5 N sodium hydroxide aqueous solution was added to the reaction solution, the mixture was extracted with ethyl acetate, and the organic layer was concentrated to obtain 8.0 g of a mixture of triglycerides or optical isomers containing unreacted trilinoleyl. The obtained mixture was separated and purified by medium pressure silica gel column chromatography ("Quick automatic purification device Isolera One", manufactured by Biotage, chromatographic column: "SNAP Ultra", manufactured by Biotage, eluted with hexane:ethyl acetate = 90:10 to 0:100), thereby obtaining di(cis,cis-9,12-octadecadienoyl)(10-hydroxy-cis-12-octadecenoyl)glycerol (3.5 g).

[0147] Melting point: below -20℃;

[0148] 1H NMR (CDCl3, 500MHz): (δ)ppm: 0.89 (t, 9H, J = 7.0Hz), 1.30 (m, 44H), 1.46 (m, 2H), 1.61 (m, 6H), 2.05 (dt, 10H, J=6.8, 7.0Hz), 2.21 (dd, 2H, J=6.6, 6.6Hz), 2.31 (m, 6H), 2.77 (dd, 4H, J=6.6, 6 .6Hz), 3.61 (m, 1H), 4.14 (d, 1H, J = 11.9Hz), 4.15 (d, 1H, J = 11.9Hz), 4.29 (d, 1H, J = 11.9Hz), 4 .30 (d, 1H, J = 11.9Hz), 5.26 (tt, 1H, J = 4.4, 5.8Hz), 5.36 (m, 9H), 5.57 (dt, 1H, J = 7.3, 10.9Hz);

[0149] MS(ESI):M + 897.

[0150] [Example 2] Di(10-hydroxy-cis-12-octadecenoyl)(cis,cis-9,12-octadecadienoyl)propylene glycol

[0151] In the same manner as in Example 1, 8.0 g of the mixture obtained by the ester exchange reaction (a mixture of triglycerides or optical isomers thereof containing unreacted trilinoleyl glycerol) was separated and purified by medium-pressure silica gel column chromatography to obtain di(10-hydroxy-cis-12-octadecenoyl)(cis,cis-9,12-octadecadienoyl)propylene glycol (0.53 g).

[0152] Melting point: 7.2~7.8℃;

[0153] 1 H NMR (CDCl3, 500MHz): (δ)ppm: 0.89 (t, 9H, J = 7.0Hz), 1.30 (m, 46H), 1.46 (m, 4H), 1.59 (m, 6H), 2.05 (dt, 8H, J=7.1, 7.3Hz), 2.21 (dd, 4H, J=6.5, 6.5Hz), 2.31 (m, 6H), 2.77 (dd, 2H, J=6.6, 6. 6Hz), 3.61 (m, 2H), 4.14 (d, 1H, J=11.9Hz), 4.15 (d, 1H, J=11.9Hz), 4.28 (d, 1H, J=11.9Hz), 4. 30 (d, 1H, J = 11.9Hz), 5.26 (tt, 1H, J = 4.4, 5.9Hz), 5.36 (m, 6H), 5.57 (dt, 2H, J = 7.3, 10.9Hz);

[0154] MS(ESI):M + 915.

[0155] [Example 3] Tri(10-hydroxy-cis-12-octadecenoyl)propylene glycol

[0156] In the same manner as in Example 1, 8.0 g of the mixture obtained by the transesterification reaction (a mixture of triglycerides containing unreacted trilinoleyl glycerol or its optical isomers) was separated and purified by medium-pressure silica gel column chromatography to obtain tri(10-hydroxy-cis-12-octadecenoyl)glycerol (0.068 g).

[0157] Melting point: 20.0~21.2℃;

[0158] 1 H NMR (CDCl3, 500MHz): (δ)ppm: 0.89 (t, 9H, J=6.9Hz), 1.30 (m, 48H), 1.46 (m, 6H), 1.61 (m, 6H), 2.05 (dt, 6H, J=7.3, 7.5Hz), 2.21 (dd, 6H, J=6.7, 6.7Hz), 2.31 (m, 6H), 3.61 (tt, 3H, J=5.8, 6.2 Hz), 4.14 (d, 1H, J=11.9Hz), 4.15 (d, 1H, J=11.9Hz), 4.29 (d, 1H, J=11.9Hz), 4.30 (d, 1H, J=11. 9Hz), 5.26 (tt, 1H, J=4.4, 5.9Hz), 5.40 (dt, 3H, J=7.5, 10.8Hz), 5.57 (dt, 3H, J=7.3, 10.9Hz);

[0159] MS(ESI):M + 993.

[0160] [Comparative Example 1] Glyceryl trilinoleate

[0161] As Comparative Example 1, the commercially available product (manufactured by Tokyo Chemical Industry Co., Ltd.) of trilinolein was used.

[0162] [Comparative Example 2] 10-Hydroxy-cis-12-octadecenoic acid (HYA)

[0163] As Comparative Example 2, HYA prepared by the method described in Patent Document 2 was used.

[0164] [Experimental Example 1]

[0165] It was confirmed by visual observation whether the compounds (I) of the present invention of Examples 1 to 3, glyceryl trilinoleate of Comparative Example 1, and HYA of Comparative Example 2 were liquid or solid at standard temperature (about 20° C.).

[0166] The results are shown in Table 1 below. It can be seen that except for HYA in Comparative Example 2, all of them are liquid at standard temperature (about 20°C). The melting point is lowered by triglyceridification of HYA, and triglycerides having at least one 10-hydroxy-12-cis-octadecenoyl group exist in a liquid state at standard temperature (about 20°C).

[0167] [Experimental Example 2]

[0168] The taste of the compounds (I) of the present invention of Examples 1 to 3, trilinoleylglycerol of Comparative Example 1, and HYA of Comparative Example 2 was subjected to sensory evaluation (hereinafter referred to as taste test) by 10 panelists. After ingesting 5 mg of the sample (the sample name was concealed from the panelists during the test), the panelists evaluated the intensity, irritation, and oiliness of each of the five tastes (delicious, bitter, sour, salty, and sweet), and further performed a comprehensive evaluation.

[0169] Each evaluation forms a 5-level evaluation as described below.

[0170] Five tastes (delicious, bitter, sour, salty, sweet): strong (5 points) to weak (1 point)

[0171] Irritation: Weak (5 points) to Strong (1 point)

[0172] Oil smell: weak (5 points) ~ strong (1 point)

[0173] Overall evaluation: delicious (5 points) ~ unpalatable (1 point)

[0174] As shown in Table 1 below, the deliciousness and sweetness of the compound (I) of the present invention were improved compared with the trilinolein of Comparative Example 1 and the HYA of Comparative Example 2, and the bitterness of the compound (I) of the present invention was reduced compared with the HYA of Comparative Example 2. In addition, it was shown that the irritation was reduced by triglyceride esterification of HYA. Furthermore, it was shown that the oily taste of the compound (I) of the present invention was weaker than that of trilinolein and HYA, and it was also excellent in the comprehensive evaluation.

[0175] [Table 1]

[0176]

[0177]

[0178] From the results of Experimental Examples 1 and 2, it was confirmed that the compound (I) of the present invention is liquid at standard temperature (about 20° C.), has no irritation and has a strong taste.

[0179] [Example 4] Preparation of the compound (I) of the present invention using triglycerides of edible fats and oils as a matrix

[0180] Into a 15 mL screw-capped test tube, edible oils (0.4 g each: linseed oil, rapeseed oil, safflower oil, soybean oil, corn oil, olive oil, cottonseed oil, coconut oil), ester exchange enzyme (lipase) (Novozymes, Novozym 40086, 0.1 g), HYA (0.6 g), and 1 mL of hexane were added. After replacing the gas phase of the reaction system with nitrogen, the mixture was stirred at 40°C for 1 to 4 hours.

[0181] In Example 4, after the reaction was allowed to proceed for 1 hour, a portion of the reaction solution was subjected to component analysis using high performance liquid chromatography (system controller: "CBM-20A", pump: "LC-10ADVP" (2 units), column oven: "CTO-10AVP", automatic injection: "SIL-20ACHT", detector: "ELSD-LTII", all manufactured by Shimadzu Corporation, eluted with hexane:ethyl acetate = 90:10 to 50:50). As a result, for all edible oils and fats used as the matrix, peaks that were not observed before the reaction (peaks having the same retention time as triglycerides containing HYA as one of the constituent fatty acids) were detected.

[0182] The triglyceride mixture after the reaction was allowed to proceed for 4 hours was also subjected to component analysis by high performance liquid chromatography in the same manner as described above. For each of the analysis results after the reaction was allowed to proceed for 1 hour and after the reaction was allowed to proceed for 4 hours, the peak area ratio of the peak having the same retention time as the triglyceride containing HYA as one of the constituent fatty acids to all the peaks was calculated and is shown in FIG. Figure 1 It was shown that the ratio of the peak area occupied by the above peak (TG(H)%) increased by prolonging the reaction time, and it was confirmed that triglycerides containing HYA as one of the constituent fatty acids were produced.

[0183] Next, after the triglycerides were reacted for 1 hour using each edible oil as a matrix, the reaction products were scraped off using a thin layer chromatography TLC plate ("TLC Silica gel 60F254", manufactured by Merck), saponified and methylated, and the fatty acid composition was analyzed using a gas chromatograph ("GC-1700", manufactured by Shimadzu Corporation).

[0184] Table 2 shows the fatty acid composition of each fat or oil used as a substrate before the reaction, and Table 3 shows the fatty acid composition of the reaction product.

[0185] In addition, the numerical values ​​in Table 2 and Table 3 show the ratio (%) of the area of ​​each peak of fatty acid detected by gas chromatography to the area of ​​all peaks.

[0186] [Table 2]

[0187] (%)

[0188]

[0189] [Table 3]

[0190] (%)

[0191]

[0192] As shown in Tables 2 and 3, in the reaction product, HYA was included in the constituent fatty acids for all edible oils and fats used as the substrate, and thus it was confirmed that the reaction product was a fat and oil mixture containing the compound (I) of the present invention. This result indicates that among the acyl groups of the compound (I), in addition to the acyl group derived from HYA, there are acyl groups derived from various edible oils and fats.

[0193] The above results show that the compound (I) of the present invention can be produced by the above-mentioned Preparation Method 1 not only when the trilinoleylglycerol used in Examples 1 to 3 is used as a base but also when triglycerides of edible fats and oils are used as a base.

[0194] [Example 5] Production of compound (I) based on production method 3

[0195] Into a 20mL flask, 4mL of GY medium (glucose 2%, yeast 1%) was placed, and after HYA was added to reach 10mg / mL, each microorganism (Basidiobolus ranarum, Basidiobolus haptosporus and Pleurotus ostreatus) was inoculated, and cultured for 7 days at 28°C with a stirring speed of 120rpm. After culture, bacteria were collected by suction filtration using a nylon mesh filter (filter type: 30μm, "NY30", Merck Millipore Company), and freeze-dried bacterial cells and water were crushed with glass beads, and lipids were extracted by the Bligh-dyer method. The extracted lipids were separated by thin layer chromatography TLC plates ("TLC Silica gel 60F254", Merck Company) (hexane: ether: acetic acid = 50mL: 200mL: 2.5mL, primulin color development, 40 minutes). The results of TLC analysis of the lipid samples extracted from Basidiobolus ranarum, Basidiobolus haptosporus, and Pleurotus ostreatus were shown in Table 2. Figure 2 .

[0196] As TLC standards, castor oil having ricinoleic acid as a constituent fatty acid of triglyceride, which is a fatty acid having a hydroxyl group like HYA, triglyceride (DiRA-TG) having two ricinoleic acids refined from castor oil, and HYA as a free fatty acid were used. The spots that can be confirmed for castor oil are, from the bottom, the spots for triglyceride having three ricinoleic acids as constituent fatty acids, the spots for triglyceride having two ricinoleic acids, and the spots for triglyceride having one ricinoleic acid. The positions of the spots for HYA as a free fatty acid and the spots that can be confirmed for castor oil are compared with the spots that can be confirmed for samples 2, 3, and 6 ( Figure 2 As a result of comparison of the spots TLC1 to 5 shown in FIG. 1 , it can be considered that the spots TLC2 to TLC5 are spots of triglycerides.

[0197] Each spot (TLC1 to 5) was scraped off from the TLC plate, saponified and methylated, and the fatty acid composition was analyzed using a gas chromatograph ("GC-1700", manufactured by Shimadzu Corporation). The analysis of the fatty acid composition of the lipids obtained from each microorganism is shown in the figure. Figure 3 .like Figure 3 As shown in FIG. 1 , it was confirmed that the triglyceride fraction of lipids extracted from each microorganism contained HYA as a constituent fatty acid. From this result, it was found that compound (I) can also be produced according to Production Method 3.

[0198] Industrial Applicability

[0199] It was found that the compound (I) of the present invention is liquid at room temperature, tastes good, and is easy to take and handle. In addition, the triglyceride or its optical isomer of the present invention hydrolyzes the ester bond in the body by lipase or the like after taking it, and HYA is released. Therefore, it is expected to exert excellent physiological functions (improvement of lipid metabolism abnormalities, improvement of intestinal immunity, inhibition of intestinal inflammation, etc.) in the same way as taking HYA alone. Therefore, it is extremely industrially applicable in that it can be used as an edible oil and fat that utilizes the above functions, can be used as various foods and food additives, and can be used in various fields such as pharmaceuticals, cosmetics, and feed.

[0200] This application is based on Japanese Patent Application No. 2015-112604 filed in Japan, and all the contents are incorporated herein by reference.

Claims

1. A triglyceride or an optical isomer thereof, wherein: One fatty acid forming an ester bond with the hydroxyl group of glycerol is 10-hydroxy-cis-12-octadecenoic acid, or wherein two fatty acids forming an ester bond with the hydroxyl group of glycerol are 10-hydroxy-cis-12-octadecenoic acid, Among them, among the fatty acids forming an ester bond with the hydroxyl group of glycerol, the fatty acid other than 10-hydroxy-cis-12-octadecenoic acid is linoleic acid.

2. The triglyceride or optical isomer thereof according to claim 1, which is liquid at room temperature.

3. An edible fat or oil comprising the triglyceride or an optical isomer thereof according to claim 1 or 2.

4. A food or food additive comprising the triglyceride or optical isomer thereof according to claim 1 or 2.

5. A pharmaceutical composition comprising the triglyceride or optical isomer thereof according to claim 1 or 2.

6. A preventive or therapeutic agent for a disease, comprising the triglyceride or optical isomer thereof according to claim 1 or 2, wherein the disease is selected from obesity, diabetes, abnormal lipid metabolism, hyperlipidemia, fatty liver, ulcerative colitis, Crohn's disease, ulcer, irritable bowel syndrome, and inflammatory diseases.

7. A cosmetic or cosmetic additive comprising the triglyceride or an optical isomer thereof according to claim 1 or 2.

8. A feed or feed additive comprising the triglyceride or optical isomer thereof according to claim 1 or 2.